Advertisement

Topics

Clementia reports results from Phase 2 trial of palovarotene to treat fibrodysplasia ossificans progressiva

19:00 EDT 17 Oct 2016 | Net Resources International

Clementia Pharmaceuticals has announced top-line results from its Phase 2 clinical trial investigating palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).

Original Article: Clementia reports results from Phase 2 trial of palovarotene to treat fibrodysplasia ossificans progressiva

NEXT ARTICLE

More From BioPortfolio on "Clementia reports results from Phase 2 trial of palovarotene to treat fibrodysplasia ossificans progressiva"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...